GlassScriptPhysician profile
Katherine S Lammers
NPI 1760481675
$1,350.91
in general payments reported to CMS, 2019-2025
25 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $116 · 2021: $53.44 · 2022: $87.51 · 2023: $241 · 2024: $263 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $221.68 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $124.38 | 2024-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $114.19 | 2019-2024 | |
| Novo Nordisk INC | $106.23 | 2023-2024 | Wegovy |
| Exeltis, USA INC. | $105.93 | 2022-2024 | Slynd |
| Biogen, INC. | $85.05 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $76.49 | 2019-2024 | Paragard T 380a |
| Allergan, INC. | $72.34 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.44 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $45.57 | 2019-2020 | |
| Therapeuticsmd, INC. | $39.66 | 2019 | |
| Millicent US INC | $37.01 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Organon LLC | $28.34 | 2024 | |
| Lupin INC. | $27.72 | 2019-2020 | |
| Avion Pharmaceuticals | $26.64 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $24.83 | 2022 | |
| Dexcom, INC. | $23.99 | 2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $19.86 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.35 | 2021 | |
| Mayne Pharma Commercial LLC | $18.21 | 2025 | |
| Lilly USA, LLC | $16.63 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $16.47 | 2023 | Gardasil 9 |
| Mission Pharmacal Company | $15.80 | 2019 | |
| Smith+Nephew, INC. | $15.71 | 2023 | Pico |
| Coloplast Corp | $15.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Lammers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.